Omnia Molecular was launched in 2006 and suspended activity in 2016. It was devoted to the design and development of anti-infectives targeting difficult-to-treat infections. Lead compounds were synthesised and optimised using a proprietary technology platform and proved effective in several biological assays.
Image
